BioAtla, Inc. (BCAB)
Develops antibody drugs that target and kill cancer cells in solid tumors.
$3.35-0.01%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-79.7%
The outlook
BCAB is trading near its 52-week low at $3.35, well below both its 50- and 200-day moving averages, signaling a downtrend. Analyst coverage appears minimal or unavailable in the data provided. The overall sentiment leans bearish based on current technical positioning.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Market cap
$5.6M
52-wk high
$71.50
52-wk low
$3.12
50-day avg
$3.76
200-day avg
$16.86
Trailing P/E
—